NCT04707508View on ClinicalTrials.gov

Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

PHASE4CompletedINTERVENTIONAL

Enrollment

203

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

January 23, 2019

Study Completion Date

November 29, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Valsartan 80 mg and metformin

Valsartan 80 mg once daily in addition to metformin monotherapy

DRUG

Metformin

Metformin monotherapy

Trial Locations (1)

540001

Nantou Christian Hospital, Nantou City

All Listed Sponsors

lead

Nantou Christian Hospital

OTHER

NCT04707508 - Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus | Biotech Hunter | Biotech Hunter